Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. reported a net loss of $2.7 million for fiscal year 2025, an improvement from a $4.0 million loss in 2024. Total revenue was $3.0 million, derived entirely from royalty revenue, representing a 19% year-over-year increase. The company's operating loss narrowed to $2.8 million from $4.2 million, driven by reduced general and administrative expenses. Research and development expenses remained elevated at $3.1 million, reflecting continued investment in the DNase technology platform. The company ended the year with $7.9 million in cash, bolstered by a $4.0 million public offering in October 2025, providing liquidity to advance its immuno-oncology programs. The strategic review process initiated to maximize shareholder value remains ongoing.

Key Takeaways